Andrea de Bartolomeis

List of Publications by Year
in descending order

81 papers	2,823 citations	126907 33 h-index	197818 49 g-index
81 all docs	81 docs citations	81 times ranked	3720 citing authors

#	Article	IF	Citations
1	Pharmacotherapy to prevent the onset of depression following traumatic brain injury. Expert Opinion on Pharmacotherapy, 2022, 23, 255-262.	1.8	1
2	Treatment-resistant schizophrenia: Addressing white matter integrity, intracortical glutamate levels, clinical and cognitive profiles between early- and adult-onset patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 114, 110493.	4.8	9
3	Analysis of mRNA and Protein Levels of CAP2, DLG1 and ADAM10 Genes in Post-Mortem Brain of Schizophrenia, Parkinsonâ€™s and Alzheimerâ€™s Disease Patients. International Journal of Molecular Sciences, 2022, 23, 1539.	4.1	10
4	Machine Learning algorithm unveils glutamatergic alterations in the post-mortem schizophrenia brain. NPJ Schizophrenia, 2022, 8, 8.	3.6	16
5	Predicting the Severity of Lockdown-Induced Psychiatric Symptoms with Machine Learning. Diagnostics, 2022, 12, 957.	2.6	3
6	Psychological distress in patients with serious mental illness during the COVID-19 outbreak and one-month mass quarantine in Italy. Psychological Medicine, 2021, 51, 1054-1056.	4.5	104
7	Developmental trajectories in psychiatric disorders: does substance/alcohol use moderate the effects of affective temperaments as moderators of age at onset? A study in post-acute, hospitalized patients with psychotic or DSM-5 bipolar or major depressive disorders. Journal of Addictive Diseases, 2021, 39, 373-387.	1.3	3
8	Modulation of glutamatergic functional connectivity by a prototypical antipsychotic: Translational inference from a postsynaptic density immediate-early gene-based network analysis. Behavioural Brain Research, 2021, 404, 113160.	2.2	13
9	Implications of the COVID-19 pandemic for people with bipolar disorders: A scoping review. Journal of Affective Disorders, 2021, 295, 740-751.	4.1	33
10	Glutamatergic postsynaptic density in early life stress programming: Topographic gene expression of mGlu5 receptors and Homer proteins. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 96, 109725.	4.8	11
11	The concept and management of acute episodes of treatment-resistant bipolar disorder: a systematic review and exploratory meta-analysis of randomized controlled trials. Journal of Affective Disorders, 2020, 276, 970-983.	4.1	43
12	The Effects of Antipsychotics on the Synaptic Plasticity Gene Homer1a Depend on a Combination of Their Receptor Profile, Dose, Duration of Treatment, and Brain Regions Targeted. International Journal of Molecular Sciences, 2020, 21, 5555.	4.1	8
13	Safety and tolerability of antipsychotic agents in neurodevelopmental disorders: a systematic review. Expert Opinion on Drug Safety, 2020, 19, 1419-1444.	2.4	19
14	Psychotic versus non-psychotic bipolar disorder: Socio-demographic and clinical profiles in an Italian nationwide study. Australian and New Zealand Journal of Psychiatry, 2019, 53, 772-781.	2.3	19
15	Gender-related differences in patients with bipolar disorder: a nationwide study. CNS Spectrums, 2019, 24, 589-596.	1.2	15
16	Clinical and psychopathological features associated with treatment-emergent mania in bipolar-II depressed outpatients exposed to antidepressants. Journal of Affective Disorders, 2018, 234, 131-138.	4.1	16
17	Incidence, prevalence and clinical correlates of antidepressantâ€emergent mania in bipolar depression: a systematic review and metaâ€analysis. Bipolar Disorders, 2018, 20, 195-227.	1.9	60
18	Socio-demographic and clinical characterization of patients with Bipolar Disorder I vs II: a Nationwide Italian Study. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 169-177.	3.2	15

#	Article	IF	Citations
19	Patterns of Management of Patients With Dual Disorder (Psychosis) in Italy: A Survey of Psychiatrists and Other Physicians Focusing on Clinical Practice. Frontiers in Psychiatry, 2018, 9, 575.	2.6	19
20	The identification of biomarkers predicting acute and maintenance lithium treatment response in bipolar disorder: A plea for further research attention. Psychiatry Research, 2018, 269, 658-672.	3.3	21
21	Treating the Synapse in Major Psychiatric Disorders: The Role of Postsynaptic Density Network in Dopamine-Glutamate Interplay and Psychopharmacologic Drugs Molecular Actions. International Journal of Molecular Sciences, 2017, 18, 135.	4.1	57
22	Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews. BioMed Research International, 2017, 2017, 1-17.	1.9	23
23	Targets, attitudes, and goals of psychiatrists treating patients with schizophrenia: key outcome drivers, role of quality of life, and place of long-acting antipsychotics. Neuropsychiatric Disease and Treatment, 2016, 12, 99.	2.2	12
24	Switching antipsychotics: Imaging the differential effect on the topography of postsynaptic density transcripts in antipsychotic-naÃ¯ve vs. antipsychotic-exposed rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2016, 70, 24-38.	4.8	14
25	New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. Expert Review of Neurotherapeutics, 2016, 16, 483-495.	2.8	18
26	d-Aspartate drinking solution alleviates pain and cognitive impairment in neuropathic mice. Amino Acids, 2016, 48, 1553-1567.	2.7	47
27	MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamineâ€“Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective. Molecular Neurobiology, 2015, 52, 1771-1790.	4.0	15
28	Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression. International Journal of Molecular Sciences, 2015, 16, 1111-1130.	4.1	66
29	Progressive recruitment of cortical and striatal regions by inducible postsynaptic density transcripts after increasing doses of antipsychotics with different receptor profiles: Insights for psychosis treatment. European Neuropsychopharmacology, 2015, 25, 566-582.	0.7	27
30	Factor structure and reliability of the Italian adaptation of the Hypomania Check List-32, second revision (HCL-32-R2). Journal of Affective Disorders, 2015, 178, 112-120.	4.1	14
31	Patients with Poor Response to Antipsychotics Have a More Severe Pattern of Frontal Atrophy: A Voxel-Based Morphometry Study of Treatment Resistance in Schizophrenia. BioMed Research International, 2014, 2014, 1-9.	1.9	32
32	Towards a framework for treatment effectiveness in schizophrenia. Neuropsychiatric Disease and Treatment, 2014, 10, 1867.	2.2	18
33	The Glutamatergic Aspects of Schizophrenia Molecular Pathophysiology: Role of the Postsynaptic Density, and Implications for Treatment. Current Neuropharmacology, 2014, 12, 219-238.	2.9	42
34	Efficacy and Clinical Determinants of Antipsychotic Polypharmacy in Psychotic Patients Experiencing an Acute Relapse and Admitted to Hospital Stay: Results from a Cross-Sectional and a Subsequent Longitudinal Pilot Study. ISRN Pharmacology, 2014, 2014, 1-9.	1.6	6
35	The Glucocorticoid Analog Dexamethasone Alters the Expression and the Distribution of Dopamine Receptors and Enkephalin within Cortico- Subcortical Regions. Current Molecular Pharmacology, 2014, 6, 149-155.	1.5	8
36	Glutamatergic Postsynaptic Density Protein Dysfunctions in Synaptic Plasticity and Dendritic Spines Morphology: Relevance to Schizophrenia and Other Behavioral Disorders Pathophysiology, and Implications for Novel Therapeutic Approaches. Molecular Neurobiology, 2014, 49, 484-511.	4.0	116

#	Article	IF	Citations
37	The emerging role of dopamineâ€“glutamate interaction and of the postsynaptic density in bipolar disorder pathophysiology: Implications for treatment. Journal of Psychopharmacology, 2014, 28, 505-526.	4.0	38
38	Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: Relevance to schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 54, 299-314.	4.8	17
39	Dandy-Walker syndrome with psychotic symptoms: a case report. Rivista Di Psichiatria, 2014, 49, 100-2.	0.6	9
40	Intracellular pathways of antipsychotic combined therapies: Implication for psychiatric disorders treatment. European Journal of Pharmacology, 2013, 718, 502-523.	3.5	15
41	Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: Role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 46, 1-12.	4.8	61
42	Scaffolding Proteins of the Post-synaptic Density Contribute to Synaptic Plasticity by Regulating Receptor Localization and Distribution: Relevance for Neuropsychiatric Diseases. Neurochemical Research, 2013, 38, 1-22.	3.3	70
43	Affective temperaments are associated with specific clusters of symptoms and psychopathology: A cross-sectional study on bipolar disorder inpatients in acute manic, mixed, or depressive relapse. Journal of Affective Disorders, 2013, 151, 540-550.	4.1	46
44	Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: Correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses. Psychiatry Research, 2013, 210, 387-395.	3.3	69
45	Imaging brain gene expression profiles by antipsychotics: Region-specific action of amisulpride on postsynaptic density transcripts compared to haloperidol. European Neuropsychopharmacology, 2013, 23, 1516-1529.	0.7	34
46	Decreased levels of d-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia. Journal of Psychiatric Research, 2013, 47, 1432-1437.	3.1	78
47	Tobacco smoking in treatment-resistant schizophrenia patients is associated with impaired cognitive functioning, more severe negative symptoms, and poorer social adjustment. Neuropsychiatric Disease and Treatment, 2013, 9, 1113.	2.2	43
48	The Role of Intranasal Oxytocin in the Treatment of Patients with Schizophrenia: A Systematic Review. CNS and Neurological Disorders - Drug Targets, 2013, 12, 252-264.	1.4	32
49	Chronic treatment with lithium or valproate modulates the expression of Homer1b/c and its related genes Shank and Inositol 1,4,5-trisphosphate receptor. European Neuropsychopharmacology, 2012, 22, 527-535.	0.7	38
50	Combination of aripiprazole with mood stabilizers for the treatment of bipolar disorder: from acute mania to long-term maintenance. Expert Opinion on Pharmacotherapy, 2012, 13, 2027-2036.	1.8	18
51	Calcium-Dependent Networks in Dopamineâ€“Glutamate Interaction: The Role of Postsynaptic Scaffolding Proteins. Molecular Neurobiology, 2012, 46, 275-296.	4.0	50
52	Group 1 metabotropic glutamate receptors and schizophrenia. Environmental Sciences Europe, 2012, 1, 94-103.	5.5	4
53	The expression of genes involved in glucose metabolism is affected by Nâ€methylâ€Ðâ€aspartate receptor antagonism: A putative link between metabolism and an animal model of psychosis. Journal of Neuroscience Research, 2012, 90, 1756-1767.	2.9	7
54	Targeting glutamate system for novel antipsychotic approaches: Relevance for residual psychotic symptoms and treatment resistant schizophrenia. European Journal of Pharmacology, 2012, 682, 1-11.	3.5	60

#	Article	IF	Citations
55	Clozapine impairs insulin action by upâ€regulating AKT phosphorylation and Ped/Peaâ€15 protein abundance. Journal of Cellular Physiology, 2012, 227, 1485-1492.	4.1	19
56	Striatal expression of Homer1a is affected by genotype but not dystonic phenotype of tottering mice: A model of spontaneously occurring motor disturbances. Neuroscience Letters, 2011, 503, 176-180.	2.1	2
57	The acute and chronic effects of combined antipsychoticâ€“mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genes. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 184-197.	4.8	44
58	Pattern of acute induction of Homer1a gene is preserved after chronic treatment with first- and second-generation antipsychotics: effect of short-term drug discontinuation and comparison with Homer1a-interacting genes. Journal of Psychopharmacology, 2011, 25, 875-887.	4.0	40
59	Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole. Psychopharmacology, 2010, 212, 329-344.	3.1	43
60	Haloperidol induces higher Homer1a expression than risperidone, olanzapine and sulpiride in striatal sub-regions. Psychiatry Research, 2010, 177, 255-260.	3.3	38
61	HOMER1 Promoter Analysis in Parkinsonâ€™s Disease: Association Study with Psychotic Symptoms. Neuropsychobiology, 2009, 59, 239-245.	1.9	25
62	Antipsychotic and antidepressant co-treatment: Effects on transcripts of inducible postsynaptic density genes possibly implicated in behavioural disorders. Brain Research Bulletin, 2009, 79, 123-129.	3.0	31
63	Dopamine receptor subtypes contribution to Homer1a induction: Insights into antipsychotic molecular action. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 813-821.	4.8	42
64	Association of antipsychotic induced weight gain and body mass index with GNB3 gene: A meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1848-1853.	4.8	32
65	Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. International Journal of Neuropsychopharmacology, 2007, 10, 697-704.	2.1	105
66	Ketamine-related expression of glutamatergic postsynaptic density genes: Possible implications in psychosis. Neuroscience Letters, 2007, 416, 1-5.	2.1	39
67	Differential expression ofHomer 1 gene by acute and chronic administration of antipsychotics and dopamine transporter inhibitors in the rat forebrain. Synapse, 2007, 61, 429-439.	1.2	34
68	Association study between the novel functional polymorphism of the serotonin transporter gene and suicidal behaviour in schizophrenia. European Neuropsychopharmacology, 2006, 16, 268-271.	0.7	32
69	Permanent Focal Brain Ischemia Induces Isoform-Dependent Changes in the Pattern of Na+/Ca2+ Exchanger Gene Expression in the Ischemic Core, Periinfarct Area, and Intact Brain Regions. Journal of Cerebral Blood Flow and Metabolism, 2006, 26, 502-517.	4.3	83
70	Geneâ€“gene interaction between MAOA and COMT in suicidal behavior: Analysis in schizophrenia. Brain Research, 2006, 1097, 26-30.	2.2	42
71	Postsynaptic density scaffolding proteins at excitatory synapse and disorders of synaptic plasticity: implications for human behavior pathologies. International Review of Neurobiology, 2004, 59, 221-254.	2.0	32
72	Antidepressants activate CaMKII in neuron cell body by Thr286 phosphorylation. NeuroReport, 2004, 15, 2393-2396.	1.2	37

#	Article	IF	Citations
73	Selective regulation of presynaptic Calcium/Calmodulin-Dependent protein kinase II by psychotropic drugs. Biological Psychiatry, 2003, 53, 442-449.	1.3	36
74	Method for quantitative in situ hybridization histochemistry and image analysis applied for Homer1a gene expression in rat brain. Brain Research Protocols, 2003, 11, 189-196.	1.6	28
75	Acute administration of antipsychotics modulates Homer striatal gene expression differentially. Molecular Brain Research, 2002, 98, 124-129.	2.3	47
76	Homer 1a Gene Expression Modulation by Antipsychotic Drugs Involvement of the Glutamate Metabotropic System and Effects of D-Cycloserine. Neuropsychopharmacology, 2002, 27, 906-913.	5.4	60
77	Opioidergic and dopaminergic gene expression in the caudate-putamen and accumbens of the mutant mouse, tottering (tg/tg). Molecular Brain Research, 1997, 46, 321-324.	2.3	4
78	Simian virus-40 large-T antigen binds p53 in human mesotheliomas. Nature Medicine, 1997, 3, 908-912.	30.7	244
79	Lack of effect of chronic morphine treatment and naloxone-precipitated withdrawal on tyrosine hydroxylase, galanin, and neuropeptide Y mRNA levels in the rat locus coeruleus. Synapse, 1995, 19, 197-205.	1.2	18
80	Dopaminergic regulation of epileptic activity. Neurochemistry International, 1992, 20, 245-249.	3.8	17
81	Plasma HVA, tardive dyskinesia and psychotic symptoms in long-term drug-free inpatients with schizophrenia. Psychiatry Research, 1990, 33, 259-267.	3.3	7